Helix BioPharma Corp. Closes Private Placement
September 10, 2018 17:05 ET
|
Helix BioPharma Corp.
RICHMOND HILL, Ontario, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX:HBP)(FSE:HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for...
Helix BioPharma Corp. collaborator ProMab Biotechnologies to present at the CAR-TCR Summit 2018 in Boston
September 04, 2018 17:05 ET
|
Helix BioPharma Corp.
RICHMOND HILL, Ontario, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates...
Helix BioPharma Corp. Closes Private Placement
August 08, 2018 17:05 ET
|
Helix BioPharma Corp.
RICHMOND HILL, Ontario, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the...
Helix BioPharma Corp. Completes Fourth Dosing Cohort and Initiates Enrollment of the Next Cohort in U.S. Combination Treatment Study of Its Lung Cancer Drug Candidate L-DOS47
July 25, 2018 17:05 ET
|
Helix BioPharma Corp.
RICHMOND HILL, Ontario, July 25, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX:HBP) (FSE:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for...
Helix BioPharma Corp. Closes Private Placement
July 09, 2018 17:05 ET
|
Helix BioPharma Corp.
RICHMOND HILL, Ontario, July 09, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX:HBP) (FSE:HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for...
Helix BioPharma Corp. Announces Fiscal Third Quarter 2018 Results
June 12, 2018 17:16 ET
|
Helix BioPharma Corp.
RICHMOND HILL, Ontario, June 12, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX:HBP) (FRANKFURT:HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative...
Helix BioPharma Corp. Closes Private Placement
June 07, 2018 17:14 ET
|
Helix BioPharma Corp.
RICHMOND HILL, Ontario, June 07, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX:HBP) FSE:HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for...
Helix BioPharma Corp. Completes Third Dosing Cohort and Initiates Enrollment of the Next Cohort in U.S. Combination Treatment Study of Its Lung Cancer Drug Candidate L-DOS47
May 30, 2018 17:05 ET
|
Helix BioPharma Corp.
RICHMOND HILL, Ontario, May 30, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX:HBP) (FSE:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for...
Helix BioPharma Corp. Closes Private Placement
April 30, 2018 17:05 ET
|
Helix BioPharma Corp.
RICHMOND HILL, Ontario, April 30, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX:HBP) (FSE:HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for...
Helix BioPharma Corp. Announces Regulatory Approval to Dose Patients in a Phase II Randomized Study of L-DOS47 With Vinorelbine and Cisplatin
April 10, 2018 07:30 ET
|
Helix BioPharma Corp.
RICHMOND HILL, Ontario, April 10, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX:HBP) (FRANKFURT:HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative...